This company develops and markets pharmaceutical products, with a portfolio that includes 11 FDA-approved drugs, though it currently has no active involvement in rare diseases.
0
Orphan Designations
11
FDA Approvals
Latest: EDURANT PED (2024)
0
Active Trials
0
Rare Diseases
0
News (30d)
Quiet
Janssen Products, LP is a company with 0 orphan drug designations across 0 rare diseases, including 11 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
No pipeline data available yet.